Inefficacy of autologous bone marrow concentrate in stage three osteonecrosis: a randomized controlled double-blind trial

Jean-Philippe Hauzeur, Viviane De Maertelaer, Etienne Baudoux, Michel Malaise, Yves Beguin, Valérie Gangji, Jean-Philippe Hauzeur, Viviane De Maertelaer, Etienne Baudoux, Michel Malaise, Yves Beguin, Valérie Gangji

Abstract

Purpose: The fracture stage of non-traumatic osteonecrosis (ON stage 3) of the femoral head (ONFH) has an unfavourable prognosis frequently requiring total hip replacement (THR). The percentage could be lowered after core decompression. In earlier non-fracture ON stages, implantation of autologous bone marrow aspirate concentrate (BMAC) improved the effect of core decompression. The purpose was to evaluate the effect of BMAC in addition to core decompression in stage 3 ONFH.

Methods: A double blind RCT was conducted comparing two groups: core decompression plus saline injection or core decompression plus BMAC implantation. Both patients and assessors were blinded to the treatment assignments. Evaluations were done at baseline, three, six, 12, and 24 months, including pain (VAS), WOMAC, side-effects, radiological evolution including ARCO subclassifications, together with possible THR requirement. The primary endpoint was the need for THR. The second endpoints included the clinical symptoms such as pain and functional ability and the progression of the ON lesions as well as the appearance of osteoarthritis features (ARCO stage 4). Both groups included 23 hips (19 patients).

Results: No differences were found between the groups for THR requirements, clinical tests, and radiological evolution. In both groups, 15/23 hips needed THR. The radiological evolution of the ONFH lesions in term of location, extension, surface collapse, and dome depression was moderate in both groups and was not correlated with the need of THR.

Conclusions: Implantation of BMAC after core decompression did not produce any improvement of the evolution of ONFH stage 3. Level of evidence I.

Trial registration: ClinicalTrials.gov NCT01544712.

Keywords: Bone marrow aspirate concentrate; Cell therapy; Femoral head; Hip; Mesenchymal stem cells; Osteonecrosis.

References

    1. Int Orthop. 2016 Jul;40(7):1347-51
    1. Clin Orthop Relat Res. 1996 Mar;(324):169-78
    1. J Bone Joint Surg Am. 2006 Nov;88 Suppl 3:16-26
    1. J Bone Joint Surg Am. 2005 Mar;87 Suppl 1(Pt 1):106-12
    1. Arch Orthop Trauma Surg. 2010 Jul;130(7):859-65
    1. Bone. 2011 Nov;49(5):1005-9
    1. Rheumatol Rehabil. 1982 Nov;21(4):211-7
    1. Int Orthop. 2011 Jun;35(6):823-9
    1. J Bone Joint Surg Br. 1999 Mar;81(2):349-55
    1. Clin Orthop Relat Res. 2002 Dec;(405):14-23
    1. J Bone Joint Surg Br. 1995 Nov;77(6):870-4
    1. J Bone Joint Surg Am. 2015 Oct 7;97(19):1604-27
    1. J Rheumatol. 2003 Feb;30(2):348-51
    1. J Bone Joint Surg Am. 1997 Nov;79(11):1699-709
    1. Clin Orthop Relat Res. 1991 Jul;(268):140-51
    1. J Bone Joint Surg Am. 1989 Jun;71(5):641-9
    1. J Rheumatol. 1988 Dec;15(12):1833-40
    1. Rev Rhum Mal Osteoartic. 1971 Apr;38(4):269-76
    1. J Bone Joint Surg Am. 2004 Jun;86-A(6):1153-60
    1. Int Orthop. 2009 Jun;33(3):639-42
    1. J Bone Joint Surg Am. 2010 Sep 15;92(12):2165-70
    1. Clin Rheumatol. 2014 Dec;33(12):1791-5
    1. Clin Rheumatol. 1986 Sep;5(3):346-58

Source: PubMed

3
Suscribir